Related Experiment Video
Updated: Dec 17, 2025
09:29
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
30.7K
Exportin 1 inhibition as antiviral therapy
Md Hafiz Uddin1, Jeffrey A Zonder1, Asfar S Azmi1
1Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA.
Drug Discovery Today
|June 23, 2020
Summary
Exportin 1 (XPO1) inhibitors, initially for cancer, show promise in blocking viral replication by trapping viral components in the host cell nucleus. Clinical trials are underway to evaluate XPO1 inhibitors for treating COVID-19 infections.
Area of Science:
- Virology
- Oncology
- Cell Biology
Background:
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes the global health crisis, COVID-19.
- Exportin 1 (XPO1) is a key protein involved in nucleocytoplasmic transport.
- XPO1 inhibitors have been developed as anticancer agents.
Purpose of the Study:
- To investigate the potential of inhibiting nuclear export as a therapeutic strategy against viral infections, including SARS-CoV-2.
- To explore the repurposing of XPO1 inhibitors for treating COVID-19.
Main Methods:
- Blocking nucleocytoplasmic transport using XPO1 inhibitors.
- Quarantining viral accessory proteins and genomic materials within the host cell nucleus.
- Evaluating the reduction in virus replication and immunopathogenicity.
Main Results:
- Previous studies demonstrated that XPO1 inhibition can reduce replication and immunopathogenicity of various viruses.
- Blocking XPO1 effectively sequesters viral components in the nucleus, limiting their spread.
- XPO1 inhibitors show potential for broad-spectrum antiviral activity.
Conclusions:
- Inhibition of nuclear export via XPO1 is a viable strategy against viral infections like SARS-CoV-2.
- XPO1 inhibitors represent a promising therapeutic avenue for COVID-19.
- Ongoing clinical studies are assessing the efficacy of selinexor, an XPO1 inhibitor, for COVID-19 treatment.
Related Concept Videos
01:30Enzyme Inhibition
89.9K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
89.9K
01:52Eukaryotic Transcription Inhibitors
10.8K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.8K
02:33Retroviruses
14.4K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
14.4K
01:10Retrovirus Life Cycles
48.9K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
48.9K